Pharmatalkradio

What is the impact of targeted radiotherapy on the immune system?What are the implications for combination IO?Current approaches and future direction Moderated by: Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, Amgen Panelists: Charles Glaus, PhD, Sr Director, Radiomics & Radiology Biomarkers, Bayer US-PharmaceuticalsJeff Legos, PhD, MBA, EVP, Global Head of Oncology & Hematology Development , NovartisMatthew Silva, PhD, CEO , InvicroOhad Ilovich, PhD, Senior Director, Translational Sciences, Curie Therapeutics Learn more about the IO360° Summit at www.io360summit.com